Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis
<p>Subcutaneous body weight-adjusted low molecular weight heparin (LMWH) has been proven as effective and safe as intravenous aPTT-adjusted unfractionated heparin (UFH) for the treatment of patients with acute deep venous thrombosis (DVT). In this study we evaluate the efficacy of the initial...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2003
|
| In: |
Thrombosis and haemostasis
Year: 2003, Jahrgang: 90, Heft: 08, Pages: 252-259 |
| ISSN: | 2567-689X |
| DOI: | 10.1160/TH02-09-0061 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1160/TH02-09-0061 Verlag, lizenzpflichtig, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1160/TH02-09-0061 
|
| Verfasserangaben: | Hanno Riess, Klaus Koppenhagen, Alexander Tolle, Bettina Kemkes-Matthes, Michael Gräve, Frantisek Patek, Michael Drexler, Hans-Joachim G. Siemens, Job Harenberg, Gottfried Weidinger, Joachim Brom, Sylvia Haas |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 180000141X | ||
| 003 | DE-627 | ||
| 005 | 20220820170722.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220421s2003 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1160/TH02-09-0061 |2 doi | |
| 035 | |a (DE-627)180000141X | ||
| 035 | |a (DE-599)KXP180000141X | ||
| 035 | |a (OCoLC)1341459200 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Riess, Hanno |d 1950- |e VerfasserIn |0 (DE-588)12015854X |0 (DE-627)080486991 |0 (DE-576)165469099 |4 aut | |
| 245 | 1 | 0 | |a Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis |c Hanno Riess, Klaus Koppenhagen, Alexander Tolle, Bettina Kemkes-Matthes, Michael Gräve, Frantisek Patek, Michael Drexler, Hans-Joachim G. Siemens, Job Harenberg, Gottfried Weidinger, Joachim Brom, Sylvia Haas |
| 264 | 1 | |c 2003 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Elektronische Reproduktion der Druck-Ausgabe 06. Dezmber 2017 | ||
| 500 | |a Gesehen am 21.04.2022 | ||
| 520 | |a <p>Subcutaneous body weight-adjusted low molecular weight heparin (LMWH) has been proven as effective and safe as intravenous aPTT-adjusted unfractionated heparin (UFH) for the treatment of patients with acute deep venous thrombosis (DVT). In this study we evaluate the efficacy of the initial treatment of proximal DVT with a fixed-dose, body weight-independent application of the LMWH Certoparin with a six month follow-up.</p> <p>In a prospective, multicentre, randomized, active-controlled study 1220 patients with objectively diagnosed proximal DVT were randomly assigned to subcutaneous 8000 U anti-factor Xa of Certoparin twice daily for 10 to 14 days or intravenous aPTT-adjusted UFH for 5 to 8 days. Both regimen were followed by oral anticoagulation for 6 months. The primary end point was the rate of symptomatic and objectively confirmed thromboembolic events within 6 months. The aim of the study was to demonstrate the non-inferiority of the Certoparin regimen as compared to UFH.</p> <p>The per-protocol analysis revealed 22 (3.8%) thromboembolic events in the Certoparin group and 24 (4.3%) in patients assigned to UFH within 6 months, thereby proving the non-inferiority (p<0.01), confirmed by intent-to-treat analysis (p<0.001). Major bleeding occurred in 6 and 7 patients started on Certoparin or UFH during the treatment period. Thromboembolic events were equally distributed in body weight categories with < 50,50-80 and >80 kg as followed:0,3.6% and 4.1% of patients for the Certoparin group and 0, 4.6% and 4.2% of patients for the UFH group. The same was true for major bleeding complications with 0, 2.9% and 1.5% for Certoparin and 0, 3.5% and 4.2% for UFH. Overall mortality was 1.9 % in the Certoparin group and 2.7 % in the UFH group.</p> <p>Fixed-dose body weight-independent subcutaneous LMWH Certoparin is at least as efficacious and safe as intravenous aPTT-adjusted UFH for the initial treatment of acute proximal DVT. This effect is maintained during a 6-months follow-up of treatment with oral anticoagulation.</p> | ||
| 700 | 1 | |a Koppenhagen, Klaus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tolle, Alexander |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kemkes-Matthes, Bettina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gräve, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Patek, Frantisek |e VerfasserIn |4 aut | |
| 700 | 1 | |a Drexler, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Siemens, Hans-Joachim G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Harenberg, Job |d 1950- |e VerfasserIn |0 (DE-588)108825507 |0 (DE-627)655891498 |0 (DE-576)339563745 |4 aut | |
| 700 | 1 | |a Weidinger, Gottfried |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brom, Joachim |e VerfasserIn |4 aut | |
| 700 | 1 | |a Haas, Sylvia |e VerfasserIn |0 (DE-588)131629379 |0 (DE-627)51171243X |0 (DE-576)298636085 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thrombosis and haemostasis |d Stuttgart : Thieme, 1976 |g 90(2003), 08, Seite 252-259 |h Online-Ressource |w (DE-627)302723188 |w (DE-600)1492370-1 |w (DE-576)079877362 |x 2567-689X |7 nnas |a Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis |
| 773 | 1 | 8 | |g volume:90 |g year:2003 |g number:08 |g pages:252-259 |g extent:8 |a Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis |
| 856 | 4 | 0 | |u https://doi.org/10.1160/TH02-09-0061 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://www.thieme-connect.de/DOI/DOI?10.1160/TH02-09-0061 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220421 | ||
| 993 | |a Article | ||
| 994 | |a 2003 | ||
| 998 | |g 108825507 |a Harenberg, Job |m 108825507:Harenberg, Job |d 60000 |d 61300 |d 60000 |e 60000PH108825507 |e 61300PH108825507 |e 60000PH108825507 |k 0/60000/ |k 1/60000/61300/ |k 0/60000/ |p 9 | ||
| 999 | |a KXP-PPN180000141X |e 4119823350 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Hanno Riess, Klaus Koppenhagen, Alexander Tolle, Bettina Kemkes-Matthes, Michael Gräve, Frantisek Patek, Michael Drexler, Hans-Joachim G. Siemens, Job Harenberg, Gottfried Weidinger, Joachim Brom, Sylvia Haas"]},"origin":[{"dateIssuedKey":"2003","dateIssuedDisp":"2003"}],"id":{"doi":["10.1160/TH02-09-0061"],"eki":["180000141X"]},"physDesc":[{"extent":"8 S."}],"relHost":[{"id":{"zdb":["1492370-1"],"eki":["302723188"],"doi":["10.1055/s-00035024"],"issn":["2567-689X"]},"origin":[{"dateIssuedKey":"1976","publisher":"Thieme ; Schattauer","dateIssuedDisp":"1976-","publisherPlace":"Stuttgart ; Stuttgart"}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Thrombosis and haemostasis","title":"Thrombosis and haemostasis","subtitle":"journal of the International Society on Thrombosis and Haemostasis"}],"recId":"302723188","language":["eng"],"note":["Gesehen am 15.06.2018"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosisThrombosis and haemostasis","part":{"volume":"90","text":"90(2003), 08, Seite 252-259","extent":"8","year":"2003","issue":"08","pages":"252-259"},"pubHistory":["35.1976 -"]}],"person":[{"roleDisplay":"VerfasserIn","display":"Riess, Hanno","role":"aut","family":"Riess","given":"Hanno"},{"family":"Koppenhagen","given":"Klaus","roleDisplay":"VerfasserIn","display":"Koppenhagen, Klaus","role":"aut"},{"display":"Tolle, Alexander","roleDisplay":"VerfasserIn","role":"aut","family":"Tolle","given":"Alexander"},{"roleDisplay":"VerfasserIn","display":"Kemkes-Matthes, Bettina","role":"aut","family":"Kemkes-Matthes","given":"Bettina"},{"role":"aut","display":"Gräve, Michael","roleDisplay":"VerfasserIn","given":"Michael","family":"Gräve"},{"family":"Patek","given":"Frantisek","display":"Patek, Frantisek","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Drexler, Michael","roleDisplay":"VerfasserIn","role":"aut","family":"Drexler","given":"Michael"},{"family":"Siemens","given":"Hans-Joachim G.","roleDisplay":"VerfasserIn","display":"Siemens, Hans-Joachim G.","role":"aut"},{"display":"Harenberg, Job","roleDisplay":"VerfasserIn","role":"aut","family":"Harenberg","given":"Job"},{"family":"Weidinger","given":"Gottfried","roleDisplay":"VerfasserIn","display":"Weidinger, Gottfried","role":"aut"},{"family":"Brom","given":"Joachim","display":"Brom, Joachim","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","display":"Haas, Sylvia","roleDisplay":"VerfasserIn","given":"Sylvia","family":"Haas"}],"title":[{"title":"Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis","title_sort":"Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Elektronische Reproduktion der Druck-Ausgabe 06. Dezmber 2017","Gesehen am 21.04.2022"],"recId":"180000141X","language":["eng"]} | ||
| SRT | |a RIESSHANNOFIXEDDOSEB2003 | ||